Ironwood Pharmaceuticals Q1 2024 Adj EPS $(0.02) Misses $0.19 Estimate, Sales $74.877M Miss $105.804M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported Q1 2024 adjusted EPS of $(0.02), missing the $0.19 estimate, and sales of $74.877M, missing the $105.804M estimate. This represents a significant decrease in performance compared to the same period last year.

May 09, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ironwood Pharmaceuticals reported a significant miss in both EPS and sales for Q1 2024, indicating a substantial decrease from the previous year's performance.
The substantial miss in both earnings per share and sales compared to analyst estimates, along with a significant decrease from the previous year's figures, suggests a negative short-term impact on IRWD's stock price. The magnitude of the miss and the comparison to last year's performance are critical factors likely to influence investor sentiment negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100